• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

    3/8/24 2:00:18 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVO alert in real time by email
    For Immediate Release:
    March 08, 2024

    Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a group of diseases of the heart and blood vessels. 

    “Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight,” said John Sharretts, M.D., director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research. “This patient population has a higher risk of cardiovascular death, heart attack and stroke. Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health.” 

    Obesity or overweight affect approximately 70% of American adults. Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke. 

    Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Therefore, Wegovy should not be used in combination with other semaglutide-containing products or other GLP-1 receptor agonists. 

    Wegovy’s efficacy and safety for this new indication were studied in a multi-national, multi-center, placebo-controlled double-blind trial that randomly assigned over 17,600 participants to receive either Wegovy or placebo. Participants in both groups also received standard-of-care medical treatment (e.g., management of blood pressure and cholesterol) and healthy lifestyle counseling (including diet and physical activity). Wegovy significantly reduced the risk of major adverse cardiovascular events (cardiovascular death, heart attack and stroke), which occurred in 6.5% of participants who received Wegovy compared to 8% of participants who received placebo.

    The prescribing information for Wegovy contains a boxed warning to inform health care professionals and patients about the risk of thyroid C-cell tumors. Because of this risk, Wegovy should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with a rare condition called Multiple Endocrine Neoplasia syndrome type 2.

    Wegovy should not be used in patients with a history of a severe allergic reaction to semaglutide or to any of the other ingredients. Patients should stop Wegovy immediately and seek medical help if a severe allergic reaction is suspected. 

    Wegovy also contains warnings for inflammation of the pancreas (pancreatitis), gallbladder problems (including gallstones), low blood sugar, acute kidney injury, hypersensitivity reactions, diabetic retinopathy (damage to the eye's retina), increased heart rate and suicidal behavior or thinking. Patients should discuss with their health care provider if they have symptoms of pancreatitis or gallstones. If Wegovy is used with insulin or with a medication that causes insulin secretion, patients should speak to their health care provider about the risk of low blood sugar. Healthcare professionals should monitor patients for kidney disease, diabetic retinopathy and depression or suicidal behaviors or thoughts.

    The most common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar) in patients with diabetes, flatulence (gas buildup) and gastroesophageal reflux disease (heartburn).

    Wegovy received Priority Review designation for this indication.

    The FDA granted the approval to Novo Nordisk A/S. 

    Wegovy is also approved to reduce excess weight and maintain weight reduction long term in certain adults with obesity or overweight and certain children with obesity, for use in addition to a reduced calorie diet and increased physical activity.

    Related Information

    Related Information
    • NIH: Overweight & Obesity Statistics

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    301-796-4540
    Consumer:
    888-INFO-FDA

     
    Get the next $NVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVO

    DatePrice TargetRatingAnalyst
    4/17/2025$64.00Outperform → Market Perform
    BMO Capital Markets
    3/13/2025Hold → Buy
    Kepler
    3/3/2025Buy → Hold
    Stifel
    2/12/2025Equal-Weight
    Morgan Stanley
    1/6/2025Underperform → Mkt Perform
    Bernstein
    5/30/2024$156.00Buy
    Goldman
    4/12/2024$163.00Outperform
    BMO Capital Markets
    1/23/2024$120.00Overweight
    Morgan Stanley
    More analyst ratings

    $NVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer

      The Wegovy® savings offer is good for all dose strengths of Wegovy® Eligible cash-paying patients can redeem this offer at the retail pharmacy of their choicePLAINSBORO, N.J., March 24, 2025 /PRNewswire/ -- Today, Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced cost of $499 per month. Until today, the $499-per-month offer for Wegovy® was only available via the recently launched NovoCare® Pharmacy. "At Novo Nordisk, we are committed to developing innovative medicines and will continue to prioritize making them acces

      3/24/25 8:00:00 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients

      NovoCare® Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost of $499 per month for cash-paying patients While 90% of patients taking Wegovy ® have a co-pay of $0 to $25 per month, this offer was designed to support cash-paying patients without insurance coverageAmidst the dangers of fake or illegitimate compounded "semaglutide," NovoCare® Pharmacy offers reliable access to authentic, FDA-approved Wegovy® in our once-weekly, single-dose pen PLAINSBORO, N.J., March 5, 2025 /PRNewswire/ -- As part of its ongoing efforts to ensure patients who need Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can access i

      3/5/25 8:00:00 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk

      MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs today launched NVOX, the world's first single-stock leveraged ETF for the pharmaceutical stock Novo Nordisk (NYSE:NVO). As the weight loss market continues to expand and Novo Nordisk is a key provider in that space, NVOX offers retail investors 2X daily long leveraged exposure to the change in the daily share price of Novo Nordisk without the need for a margin account. This provides a unique tool for tactical traders. NVOX does not invest directly in Novo Nordisk and has a higher degree of risk due to tracking a single stock. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark, seeking to

      12/3/24 6:00:00 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

      3/8/24 2:00:18 PM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Novo Nordisk A/S downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Novo Nordisk A/S from Outperform to Market Perform and set a new price target of $64.00

      4/17/25 8:30:12 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk A/S upgraded by Kepler

      Kepler upgraded Novo Nordisk A/S from Hold to Buy

      3/13/25 8:17:45 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk A/S downgraded by Stifel

      Stifel downgraded Novo Nordisk A/S from Buy to Hold

      3/3/25 7:34:14 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    SEC Filings

    See more
    • SEC Form 6-K filed by Novo Nordisk A/S

      6-K - NOVO NORDISK A S (0000353278) (Filer)

      5/9/25 8:12:45 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Novo Nordisk A/S

      6-K - NOVO NORDISK A S (0000353278) (Filer)

      5/7/25 8:01:16 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Novo Nordisk A/S

      6-K - NOVO NORDISK A S (0000353278) (Filer)

      4/3/25 6:05:06 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • EXL Announces Appointment of Andreas Fibig to Board of Directors

      NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees. "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We lo

      1/12/23 4:01:00 PM ET
      $EXLS
      $IFF
      $NVO
      Business Services
      Consumer Discretionary
      Major Chemicals
      Industrials
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,

      12/1/20 4:30:00 PM ET
      $LLY
      $DRNA
      $NVO
      $ALXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals